BIA Separations

Executive Summary

BIA Separations, a subsidiary of Sartorius since its acquisition, is a leading provider of monolithic chromatography solutions for the purification and analysis of large biomolecules, including viral vectors, nucleic acids, and lipid nanoparticles. The company's proprietary monolith columns enable high-productivity, scalable processing critical for advanced therapies such as gene therapies and mRNA vaccines. As part of the Sartorius group, BIA Separations benefits from expanded commercial reach and investment in R&D, but operates within a niche segment of the bioprocessing market. The technology is well-positioned to capture growth as the demand for viral vector and mRNA manufacturing capacity surges, driven by ongoing clinical development and commercialization of cell and gene therapies. However, competition from traditional resin-based and alternative purification methods remains a risk. Overall, BIA Separations' unique monolith platform and integration with a global life science leader provide a solid foundation for capturing market share in the high-growth advanced therapy manufacturing space.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation monolithic column for mRNA/LNP purification70% success
• Q2 2027Expansion of manufacturing capacity at Ajdovščina facility to meet demand80% success
• Q3 2026Strategic partnership with a top-10 gene therapy developer for commercial supply60% success